Addressing the Ongoing Challenges of Particulate Matter in Injectable Solutions

Do you see hair in this injectable solution?

Injectable solutions are critical in modern medicine, delivering life-saving drugs directly into the body.  Despite advances in pharmaceutical technology, the presence of particulate matter in these solutions remains a significant concern.  Particulate contamination can compromise patient safety, affect drug efficacy, and lead to serious health complications. This issue has persisted for decades, prompting ongoing research and regulatory efforts to minimize risks.  This article explores why particulate matter continues to challenge injectable solutions, the sources of contamination, detection methods, and strategies to reduce its presence.

Understanding Particulate Matter in Injectable Solutions

Particulate matter refers to tiny, often microscopic, solid or liquid particles suspended in injectable fluids. These particles can vary in size, shape, and composition. They may include:

• Glass shards from vial or ampoule breakage

• Rubber fragments from stoppers or seals

• Metal particles from manufacturing equipment

• Fibers from packaging materials (i.e. polypropylene bags or fabrication of bags)

• Crystals formed by drug precipitation or degradation

• Hair/Contaminants from operators (see photos)

Injecting particulate matter can cause inflammation, embolism, allergic reactions, or infections, and even death. Regulatory agencies like the FDA and EMA set strict limits on allowable particulate levels in injectable products to protect patients.

Why Particulate Matter Remains a Problem

Despite decades of awareness and technological improvements, particulate contamination persists due to several factors:

·       Complex Manufacturing Processes: Injectable drugs often require multiple steps, including mixing, filtration, filling, and sealing.  Each step introduces opportunities for contamination. For example, glass vials can shed tiny particles during filling or transport. Rubber stoppers may degrade or shed fragments over time. 

·       Limitations of Filtration: Sterile filtration is a standard step to remove bacteria and particles. However, filters have pore size limits and may not catch all particles, especially those smaller than the filter rating or those that form after filtration.  Some drug formulations also interact with filters, reducing filtration efficiency.

·       Drug Formulation Challenges: Certain drugs are prone to crystallization or aggregation, especially biologics like monoclonal antibodies. These particles can form inside the vial after manufacturing, making them difficult to control.  Changes in temperature, pH, or storage conditions can worsen this problem.

·       Poor Visual Inspection Program: FDA expects 100% visual inspection of all units produced.  Often times, company’s probability of detection of particulates is inadequate.  The FDA expects that the probability of detection to be at minimum 70% for certain particulates larger than 150 microns (i.e. dark fibers, light fibers, glass, etc.)

·       Packaging and Handling: Particles can enter solutions during packaging or handling.  For example, fibers from gloves or clothing, dust from the environment, or particles from equipment can contaminate the product. Even careful cleanroom environments cannot guarantee zero particulate presence. 

Detecting Particulate Matter in Injectable Solutions per USP <771>, <787>, <788>, <789>, <1787>, <1788>, and <1790>

Detecting particles in injectable solutions requires sensitive and reliable methods. Some common techniques include:

• Light Obscuration (LO): Measures particles by detecting light blocked by particles passing through a sensor. It is widely used for particles larger than 2 micron.

• Membrane Filtration Microscopy (MFM): Visual inspection under a microscope helps identify particle size, shape, and type. It is labor-intensive but provides detailed information.  The MFM method is superior to LO method for capturing and characterizing larger foreign particles in the visible range (>100 μm).

• Flow Imaging Microscopy: Combines flow cytometry and imaging to analyze particles in liquid samples.

• Dynamic Light Scattering: Measures size distribution of submicron particles, useful for protein aggregates.

• Visual Inspection: a manual and/or automated process aimed at detecting visible particulates greater than 100 μm in size.  A defined inspection environment is crucial for reliable outcomes, and operators must be trained for effective assessment.

Regulatory guidelines require manufacturers to perform routine particulate testing during production and before release.

Strategies to Reduce Particulate Contamination

Pharmaceutical companies use multiple approaches to minimize particulate matter in injectable solutions:

·       Improved Raw Materials and Components: Using high-quality glass vials with low particulate shedding, and rubber stoppers designed to minimize fragment release, reduces contamination risk. Suppliers are often audited to ensure material quality.

·       Enhanced Filtration Techniques: Employing multiple filtration steps with different pore sizes can improve particle removal. Advances in filter materials and designs also help reduce particle shedding from filters themselves.

·       Optimized Manufacturing Processes: Automation reduces human contact and environmental exposure. Cleanroom standards are strictly enforced to limit airborne particles.

·       Equipment maintenance: Equipment is regularly maintained and cleaned to prevent metal or rubber debris.

·       Formulation Adjustments: Stabilizing drug formulations to prevent crystallization or aggregation helps reduce particle formation. This may include adjusting pH, adding stabilizers, or controlling storage conditions.

·       Packaging Innovations: Using pre-sterilized, low-particulate packaging materials and minimizing handling steps during filling and sealing reduce contamination. Some manufacturers use single-use systems to avoid cross-contamination.

·       Training and protocols: Ensuring staff follow best practices reduces human error.

Real-World Examples of Particulate Contamination Issues

Several incidents highlight the ongoing challenges:

• B. Braun Medical, Inc. Issues Voluntary Nationwide Recall of Lactated Ringer’s Injection, 1L, E7500 Due to the Presence of Particulate Matter in Solution | FDA 

• Provepharm Inc. Issues Voluntary Nationwide Recall of One Lot of Phenylephrine Hydrochloride Injection, USP, 10 mg/ mL (Pharmacy Bulk Package) Due to Presence of Particulate Matter | FDA 

• Par Health USA, LLC & Endo USA, Inc. - 722121 - 04/15/2026 | FDA Warning Letter involving particulate matter 

• Amneal Pharmaceuticals, LLC - 709894 - 08/27/2025 | FDA Warning Letter involving particulate matter

What Patients and Healthcare Providers Should Know

While manufacturers work to reduce particulate matter, healthcare providers and patients can take steps to minimize risks:

• Inspect injectable solutions visually before use for any visible particles or discoloration.

• Avoid using solutions from damaged or compromised packaging.

• Follow proper storage instructions to prevent particle formation.

• Report any adverse reactions or unusual observations to healthcare authorities.

Awareness helps catch potential issues early and protect patient safety.